Intranasal Esketamine-dexmedetomidine Combination and Postpartum Depression

Esketamine has rapid-onset antidepressant effects and may reduce postpartum depression in parturients with prenatal depressive symptoms. However, its adverse neuropsychiatric symptoms limits clinical application. Dexmedetomidine can alleviate these adverse symptoms and has independent antidepressant effect. This randomized, double-blind, placebo-controlled trial is designed to evaluate whether intranasal esketamine combined with dexmedetomidine can reduce the prevalence of postpartum depression in women with prenatal depressive symptoms.

NCT Number	NCT07639099
Lead Sponsor	Peking University First Hospital
Conditions	Parturients, Depressive Symptoms, Esketamine, Dexmedetomidine, Intranasal Administration, Postpartum Depression
Enrollment	164 participants
Start Date	2026-06
Primary Completion	2029-10 (estimated)
Study Completion	2029-12 (estimated)
Updated on ClinicalTrials.gov	2026-06-15